Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 5, 1997, Pages 462-466

  Shlebak, A A ^a,b   Smith, D B ^a  

^a CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; Chemotherapy; Thromboembolism

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUOROURACIL; HEPARIN; LEVAMISOLE; LOMUSTINE; METHOTREXATE; TAMOXIFEN; VINDESINE; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLON ADENOCARCINOMA; FEMALE; GERM CELL TUMOR; HUMAN; LUNG CANCER; LYMPHOMA; MALE; OVARY CANCER; PRIORITY JOURNAL; SEMINOMA; TESTIS CANCER; THROMBOEMBOLISM;

ADULT; AGED; ANGIOGRAPHY; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INCIDENCE; INPATIENTS; LUNG NEOPLASMS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEOPLASMS; OUTPATIENTS; OVARIAN NEOPLASMS; PHLEBOGRAPHY; TESTICULAR NEOPLASMS; THROMBOEMBOLISM;

EID: 0031054398     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050599     Document Type: Article

References (44)

1. Aranda A, Paramo JA, Cuesta B (1987) Fibrinolytic activity in malignancy (abstract). Thromb Haemost 58:110
2. Bastida E, Ordinas A, Escolor G, et al (1984) Tissue factor in microvesicles shed from U87MG human glioblastoma induces coagulation, platelet aggregation, and thrombogenesis. Blood 64:177
3. Bauer KA, Rosenberg RD (1987) The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of the haemostatic system activation. Blood 70:343
4. Cantwell BMJ, Carmichael J, Ghani SE (1988) Thrombosis and thromboembolism in lymphoma patients during remission induction by cytotoxic chemotherapy. BMJ 297:179
5. Cantwell BMJ, Mannix KA, Ghani SE, et al (1988) Thromboembolic events during combination chemotherapy for germ cell malignancy. Lancet II:1086
6. Carr JM, Dvorrak AM, Dvorak HF (1985) Circulating membrane vesicles in leukemic blood. Cancer Res 45:5944
7. Coon WW (1976) Risk factors in pulmonary embolism. Surg Gynaecol Obstet 143:385
8. Deshmukh N, Tripathi SP (1995) Thrombosis of tibial arteries in a patient receiving tamoxifen therapy. Cancer 76: 1006
9. Donati MB (1994) Cancer and thrombosis. Haemostasis 24:128
10. Dvorak HF, Quay SC, Orenstein NS, et al (1981) Tumour shedding and coagulation. Science 212:923
11. Dvorak HF, De Water L van, Bitzer AM, et al (1983) Procoagulant activity associated with plasma membrane vesicles shed by cultured tumour cells. Cancer Res 43:4434
12. Edwards RL, Silver J, Rickles FR (1993) Human tumour procoagulants. Thromb Haemost 69:205
13. Enck RE, Rios CN (1984) Tamoxifen treatment of metastatic breast cancer and antithrombin III levels. Cancer 53:2607
14. Falanga A, Ofosu FA, Cortelazzo S, et al (1993) Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 85: 745
15. Fisher MM, Hochberg LA, Wilensky ND (1951) Recurrent thrombophlebitis in obscure malignant tumour of the lung. JAMA 147:1213
16. Fossa SD, Auss N, Kaalhns O, et al (1986) Long term survival and morbidity in patients with metastatic malignant germ cell tumours treated with cisplatin-based combination chemotherapy. Cancer 58:2600
17. Goodnough LT, Saito H, Manni A, et al (1984) Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen: a study of 159 patients. Cancer 54:1264
18. Gordon SG (1992) Cancer cell procoagulants and their implications. Haematol Clin North Am 6:1359-1374
19. Gordon SG, Mourad AM (1991) The site of activation of factor X by cancer procoagulant. Blood Coagulation Fibrinolysis 2:735
20. Greaves M, Preston E (1993) Clinical and laboratory aspects of thrombophilia. Recent Adv Blood Coagulation 5:119
21. Greenberg E, Divertie MB (1964) A review of unusual systemic manifestations associated with carcinoma. Am J Med 36: 106
22. Healy B. Tormey DC, Gray R (1987) Arterial and venous thrombotic events in ECOG adjuvant breast cancer trials (abstract). Proc Am Soc Clin Oncol 6:54
23. Henddrick A, Subramunian VP (1980) Tamoxifen and thromboembolism. JAMA 243:514
24. Homans AC, et al (1987) Effects of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol 5:811
25. Wateri AH, et al (1991) Oral anti-coagulation in standard haematology practice. Edited by B. Roberts on behalf of the British Committee for standards in haematology. Blackwell, Oxford, p 73
26. Jordan VC, Fritz NF, Tormey DC (1987) Long term adjuvant therapy with tamoxifen: effects on sex hormones binding globulin and antithrombin III. Cancer Res 47:4517
27. Kakkar AK, De Ruvo N, Chinswangwatanakul V, et al (1995) Extrinsic pathway in cancer with high factor VIIa and tissue factor. Lancet 346:1004
28. Levine NM, Gent M, Hirch J, et al (1988) The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 318:404
29. Levine M, Hirsh J, Gent M, et al (1994) Double-blind randomised trial of very low dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 343:886
30. Lieberman JS, Borrero J, Wright IS (1961) Thrombophlebitis and cancer. JAMA 177:542
31. Lipton A, Harvey HA, Hamilton RW (1984) Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treat Rep 68:887
32. Love RR, Surawics TS, Williams EC (1992) Antithrombin III level. fibrinogen level, and platelet count changes with adjuvant tamoxifen therapy. Arch Intern Med 152:317
33. Lowel JA, Bothe A (1991) Venous access: preoperative, operative and postoperative dilemmas. Surg Clin North Am 71:1231
34. Nand S, Messmore H (1990) Hemostasis in malignancy. Am J Hematol 35:45
35. Nevassaari K, Heikkinen M, Taskineu PJ (1978) Tamoxifen and thrombosis. Lancet II:946
36. Patterson WP, Ringenberg QS (1990) The pathophysiology of thrombosis in cancer. Semin Oncol 17:140
37. Ruiz MA, Marugan I, Estelles P (1987) The influence of chemotherapy on the plasmatic coagulation and fibrinolytic system in lung cancer (abstract). Thromb Haemost 58: 110
38. Sarasin FP, Eckman MH (1993) Management and prevention of thromboembolic events in patients with cancer-related hypercougulable states. J Gen Intern Med 8:476
39. Sproul EE (1938) Carcinoma and venous thrombosis:the frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 566:85
40. Tripodi A, Mannucci PM, Chantarangkul V, et al (1993) Markers of procoagulant imbalance in patients with localised melanomas and autoimmune disorders. Br J Haematol 84:670
41. Trousseau A (1972) Lectures on clinical medicine delivered at the Hotel-Dieu, Paris. The New Sydenham Society, London, p 282
42. Vogetzany NJ, Bosi GJ, Hohnson K (1981) Raynaud's phenomenon: a common toxicity after combination chemotherapy for testicular cancer. Ann Intern Med 95:288
43. Weiss RB, Tormey DC, Holland JF, et al (1981) Venous thrombosis during multi-modal treatment of primary breast cancer. Cancer Treat Rep 65:677
44. Willams EC (1990) Catheter related thrombosis. Clin Radiol 13:34